Company Filing History:
Years Active: 2007-2013
Title: Ingvil Saeterdal: Innovator in Cancer Immunotherapy
Introduction
Ingvil Saeterdal is a prominent inventor based in Oslo, Norway. She has made significant contributions to the field of cancer immunotherapy, particularly through her innovative work on isolated peptides. With a total of 2 patents, her research focuses on developing therapeutic solutions that can enhance the immune response against cancer cells.
Latest Patents
Ingvil Saeterdal's latest patents involve isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer. These isolated peptides are capable of eliciting T cell immunity against cells harboring genes with such mutations. Additionally, her patents describe cancer vaccines and therapeutically effective compositions containing these peptides, showcasing her commitment to advancing cancer treatment.
Career Highlights
Saeterdal is currently associated with Gemvax AS, where she continues her groundbreaking research. Her work has the potential to revolutionize cancer therapies and improve patient outcomes.
Collaborations
Throughout her career, Ingvil has collaborated with notable colleagues such as Gustav Gaudernack and Jon Amund Eriksen. These partnerships have further enriched her research and contributed to the development of innovative cancer treatments.
Conclusion
Ingvil Saeterdal stands out as a key figure in the field of cancer immunotherapy, with her innovative patents paving the way for new therapeutic approaches. Her dedication to research and collaboration highlights the importance of innovation in combating cancer.